Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

There are plenty of fun facts about Italy. It's one of Europe's most visited countries. The history's long. The culture's rich. And the food's delectable. But what do you actually know? Here are our ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

Preparing for an interview might be one of the most stressful parts of your job search. On one hand, all your hard work fine-tuning your resume and tailoring your cover letter is paying off. But on ...

Notably, GSK’s previously sold antacid Zantac may have caused cancer in some patients. Naturally, this creates some legal risks for shareholders. So far, GSK has incurred a $2.2 billion charge ...